Early Approval For Astra's Asthma Drug Stuns Analysts

Law360, New York (July 22, 2006, 12:00 AM EDT) -- In a blow to GlaxoSmithKline Plc, rival AstraZeneca Plc has secured a surprisingly early U.S. Food and Drug Administration approval for Symbicort, an asthma drug that will compete directly with Glaxo’s blockbuster asthma treatment Advair.

AstraZeneca applied for FDA approval last September and had expected a turnaround time of about one to two years, which would be typical for a new asthma inhaler.

The FDA approved two dose strengths of the treatment for asthma in patients age 12 and older, but AstraZeneca won’t launch the drug...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.